|
|
Post by neil36 on Sept 13, 2021 15:57:00 GMT -5
NRx and IQVIA just announced a partnership. IQVIA (IQV) has a $50 billion market cap.
IQVIA headquarters is in Danbury, CT, exactly three miles southwest of the Mannkind facility.
Interesting.
———————————-
RESEARCH TRIANGLE PARK, N.C., September 13, 2021--(BUSINESS WIRE)--IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced a transformative collaboration with NRx Pharmaceuticals (NRx) (Nasdaq: NRXP). NRx is a company dedicated to creating innovative, life-saving treatments and bringing hope to those facing life-altering conditions with no approved disease-modifying therapies or cures. IQVIA is excited to collaborate with NRx as its designated partner, to provide pharmacovigilance services and medical information in preparation for potential regulatory actions.
"As the world suffers yet another surge of COVID-19, thousands of patients require intensive care and too many succumb to this virus. New medicines with new mechanisms of action are urgently needed," said Robert Besthof, chief commercial officer and head of Operations of NRx. "As a small biopharma company preparing to launch a lifesaving medicine across multiple countries, we deeply appreciate the global reach that IQVIA is able to offer in support of patients, families, and those who care for them."
This collaboration will allow NRx to access IQVIA’s domain experience with COVID-19, our unparalleled data assets, and analytics to support potential emergency use authorization (EUA) of ZYESAMI. IQVIA will work closely with NRx to support key activities required for EUA activation, including the pharmacovigilance and medical information programs.
"We are honored by the opportunity to join with NRx on the EUA activation and compliance for ZYESAMI in treating some of the sickest patients suffering from COVID-19," said Susan Kitlas, vice president, Precommercial Business Unit, IQVIA. "IQVIA’s experience and expertise within the COVID-19 market will be a valuable component in helping make this treatment more widely available."
|
|
|
|
Post by cretin11 on Sept 13, 2021 16:45:01 GMT -5
And IQVIA’s corporate presence in NC is just miles from UTHR…
🤔
|
|
|
|
Post by cedafuntennis on Sept 13, 2021 16:59:06 GMT -5
And IQVIA’s corporate presence in NC is just miles from UTHR… 🤔 Maybe Mannkind will be just the next company to relocate from California to another state. Would make perfect sense to me. |
|
|
|
Post by olderteampt on Sept 13, 2021 17:47:21 GMT -5
Bingo, MNKD just had over 270K shares traded after hours
|
|
|
|
Post by awesomo on Oct 7, 2021 0:56:42 GMT -5
|
|
|
|
Post by peppy on Oct 7, 2021 4:47:06 GMT -5
I didn't bother to read it. Amy Rosenfeld last night regarding anti virals. The Merck anti viral is an old drug that is being repurposed. Ditto the Pfizer antiviral that is going to show up. Once again the problem, Mercks' antiviral is a prophylactic drug. Additionally, a cocktail will be required. Dr. Javitt knows what he is doing is the assumption I am working with. |
|
|
|
Post by myocat on Oct 7, 2021 14:18:54 GMT -5
NRXP share price has been hammered, any idea?
|
|
|
|
Post by peppy on Oct 7, 2021 14:27:11 GMT -5
NRXP share price has been hammered, any idea? no interest? 1,049,588 Avg. Volume 5,009,396 It is being shorted to oblivion? Same song second verse, a little bit louder and a little bit worse? The FDA has its favorites? MCK and PFZ have different drugs to be repurposed. Molnupiravir a ribonucleoside analog Pfizer is making a Protease inhibitor. They need combination therapies/drugs like those used in HIV. HIV is the template. |
|
|
|
Post by myocat on Oct 8, 2021 14:47:35 GMT -5
It's another bad day for NRXP.
|
|
|
|
Post by winner on Oct 8, 2021 15:08:31 GMT -5
yup. You take your chances. You win some. You lose some. Remember the old adage, you haven't lost until you sell or the stock is delisted..
ALWAYS REMEMBER PLAY WITH WHAT YOU CAN AFFORD TO LOSE...
|
|
|
|
Post by veritasfiliatemporis on Oct 10, 2021 9:54:00 GMT -5
"Relief has reimbursed NRx Pharmaceuticals $10,904,065 for expenses, but has subsequently declined to pay approximately $6 million in invoiced costs associated with conduct of the IV clinical trial, reformulation, and manufacture of ZYESAMITM. Relief has additionally declined to fund the costs of the inhaled trial. NRx Pharmaceuticals advised Relief that NRx Pharmaceuticals is funding those costs with other capital. NRx Pharmaceuticals further advised Relief in December 2020 that the formulation data provided to NRx Pharmaceuticals as part of the collaboration agreement was non-reproducible. Relief subsequently issued a public disclosure acknowledging that Relief knew about the stability problems at the time of the collaboration agreement. Relief declined to fund the development of a stable formulation."
From 10-Q, as far as I understand it is not stable, closed position 2 weeks ago...still watching. The deal was dead already
|
|
|
|
Post by lakon on Oct 10, 2021 11:14:09 GMT -5
It seems that NRx figured out how to stabilize and mass produce the molecule where Relief failed, but now, Relief wants to enforce an essentially dead collaboration agreement because why not try to get paid? Does that about sum things up?
I suppose that means SELL Relief and BUY NRx.
|
|
|
|
Post by mymann on Oct 10, 2021 11:40:40 GMT -5
Lawsuits must be the current flavor in biotechnology. Nrxp, UTHR and Cydy are all going through this crap. I in all these companies and it's wasting good money to keep the scumbags from stealing someone's hard work.
|
|
|
|
Post by veritasfiliatemporis on Oct 10, 2021 16:01:34 GMT -5
don't know...maybe..., only wondering who is helping out NRX Pharma, IQVIA, MNKD both? BTW the price is quite low... I presume
|
|
|
|
Post by itellthefuture777 on Oct 10, 2021 23:00:30 GMT -5
It seems that NRx figured out how to stabilize and mass produce the molecule where Relief failed, but now, Relief wants to enforce an essentially dead collaboration agreement because why not try to get paid? Does that about sum things up?
I suppose that means SELL Relief and BUY NRx.
This is an interesting blog. www.thefdalawblog.com/ |
|
